Shares of Shilpa Medicare Ltd were trading in the green and 3% higher on 4 October after the company announced that its subsidiary, Shilpa Pharma Lifesciences Ltd has received CEP from EDQM. 

In its regulatory filing, the company said that Shilpa Pharma Lifesciences Limited had received a certificate of suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for the active pharmaceutical ingredient (API), desmopressin.

Desmopressin is used to lower extensive thirst and reduce frequent urination. This will also help treat both central diabetic insipidus and bedwetting.

In an exchange filing, Shilpa Medicare said, “This is to inform you that the Shilpa Medicare Limited’s 100% subsidiary, Shilpa Pharma Lifesciences Limited received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Desmopressin.”

According to Shilpa Pharma Lifesciences, desmopressin is a synthetic peptide produced by solid-phase synthesis.

Keshav Bhutada, Executive Director- Shilpa Pharma Lifesciences Limited, said, “We at Shilpa have always been investing in challenging chemical synthesis. With unwavering commitment and belief in our technical capabilities, we have invested in developing a versatile peptide portfolio over the past few years and Desmopressin is the first peptide molecule to receive CEP from the European Regulators. This CEP showcases our proficiency in quality-oriented development as well as commercial manufacturing capabilities that meet the expectations of global quality standards paving way for more such products to follow.”

Founded in 1987, Shilpa Medicare produces formulations, intermediates, and specialised active pharmaceutical ingredients (APIs). The business also provides manufacturing and contract research services to a range of customers. Its formulation portfolio consists of thirteen formulations created by its fully owned subsidiary Shilpa Therapeutics, sixteen injectable dosage forms, and nineteen oral solid dosage forms under the SML brand.

At 12:45 pm, the shares of Shilpa Medicare were trading 2.61% higher at Rs 826.75 on NSE. 

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!